Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INDUCE-4: Feladilimab + Pembrolizumab + Chemo in HNSCC
NCT04428333Phase 3Terminated
- Sponsor
- GSK
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 19
01
Overview
A Phase 3 trial of feladilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by GSK. Started Aug 2020; status: terminated.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04428333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04428333.